Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Details

Language :

English

ISSN :

21522650

Volume :

19

Database :

Complementary Index

Journal :

Clinical Lymphoma, Myeloma & Leukemia

Publication Type :

Academic Journal

Accession number :

142669381

Full Text :

https://doi.org/10.1016/j.clml.2019.07.097